Background Treatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain inadequate. Mast cells actively participate in the pathogenesis of MS, in part because ...

Real-world discontinuation rates of ocrelizumab are low, similar to pivotal trials, with rates between 3.2% and 4.1% for RRMS and PPMS. Side effects are the most common reason for discontinuation ...

These changes were mainly driven by the T25FW and 9-HPT subscores, with the clinical implications being that masitinib might slow down the degeneration of lower limb function (as evidenced by a ...

Subcutaneous ocrelizumab (SC OCR) maintains a safety profile similar to intravenous administration in multiple sclerosis patients. A 920 mg SC OCR dose was identified as optimal, with mild to ...